Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2
作者机构:Department of Integrative Medical SciencesCollege of MedicineNortheast Ohio Medical UniversityRootstownOHUSA Department of Food Science and Human NutritionChonbuk National UniversityDeokjin-guJeonjuRepublic of Korea
出 版 物:《Liver Research》 (肝脏研究(英文))
年 卷 期:2018年第2卷第4期
页 面:209-215页
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:This work was supported by USA National Institutes of Health(NIH)grant R01DK093774 to Y.K.Lee
主 题:Non-alcoholic fatty liver disease(NAFLD) High fat diet(HFD) Adipogenesis Gene expression Peroxisome proliferator-activated receptor gamma(PPARγ)
摘 要:Peroxisome proliferator-activated receptor gamma(PPARγor PPARG)is a ligand-activated transcription factor belonging to the nuclear hormone receptor *** plays a master role in the differentiation and proliferation of adipose *** has two major isoforms,PPARγ1 and PPARγ2,encoded from a single gene using two separate promoters and alternative *** them,PPARγ2 is most abundantly expressed in adipocytes and plays major adipogenic and lipogenic roles in the ***,it has been shown that PPARγ2 is also expressed in the liver,specifically in hepatocytes,and its expression level positively correlates with fat accumulation induced by pathological conditions such as obesity and *** of the hepatic Pparg gene ameliorates hepatic steatosis induced by diet or genetic *** activation of Pparg in the liver induces the adipogenic program to store fatty acids in lipid droplets as observed in *** how the hepatic Pparg gene expression is regulated will help develop preventative and therapeutic treatments for non-alcoholic fatty liver disease(NAFLD).Due to the potential adverse effect of hepatic Pparg gene deletion on peripheral tissue functions,therapeutic interventions that target PPAR g for fatty liver diseases require fine-tuning of this gene s expression and transcriptional activity。